The Swiss company's Botox competitor hits a regulatory wall, requiring additional clinical data before resubmission.
Galderma announced it received a Complete Response Letter (CRL) from the FDA for RelabotulinumtoxinA, its neuromodulator candidate positioned as a Botox alternative. The CRL indicates the agency will not approve the application in its current form and requires additional information—likely additional clinical or manufacturing data—before the company can resubmit.
This marks a significant setback for Galderma's push to capture share in the $4+ billion U.S. neuromodulator market, where AbbVie's Botox maintains dominant position despite competition from Revance's Daxxify (approved 2023) and Evolus's Jeuveau. The timing matters: practices have already begun rotating among approved toxins, and a new entrant needs regulatory certainty to build formulary relationships and rebate programs through GPOs and loyalty networks like Alle and Aspire.
Complete Response Letter signals additional data required before resubmission; no approval timeline confirmed.
The CRL does not mean rejection—it's a pathway to resubmission—but it extends Galderma's timeline and creates uncertainty around launch timing and commercial viability.
Source: original report ↗
Free alerts Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo Join the owners who run ahead of the industry. Cancel anytime, one click.
